Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1.
about
Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb bindingFc glycans of therapeutic antibodies as critical quality attributesIn vitro and in vivo modifications of recombinant and human IgG antibodiesMonocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcγRIIa polymorphisms.Immunoglobulin G1 Fc Domain Motions: Implications for Fc EngineeringKey factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and developmentThe role of constant region carbohydrate in the assembly and secretion of human IgD and IgA1High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans.Characterization of a UDP-Gal:Galbeta1-3GalNAc alpha1, 4-galactosyltransferase activity in a Mamestra brassicae cell line.Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys.Exchanging murine and human immunoglobulin constant chains affects the kinetics and thermodynamics of antigen binding and chimeric antibody autoreactivity.Production of a recombinant mouse monoclonal antibody in transgenic silkworm cocoons.Optimized expression of full-length IgG1 antibody in a common E. coli strain.Complement-Mediated Enhancement of Monocyte Adhesion to Endothelial Cells by HLA Antibodies, and Blockade by a Specific Inhibitor of the Classical Complement Cascade, TNT003Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis.Glycosylation profiling of therapeutic antibodies in serum samples using a microfluidic CD platform and MALDI-MS.Extracellular enzymes with immunomodulating activities: variations on a theme in Streptococcus pyogenesHuman immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody.Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans.Increased serum clearance of oligomannose species present on a human IgG1 molecule.Stability of IgG isotypes in serum.Assessing monoclonal antibody product quality attribute criticality through clinical studies.Recent advances in the understanding of biological implications and modulation methodologies of monoclonal antibody N-linked high mannose glycans.Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms.Engineering novel Lec1 glycosylation mutants in CHO-DUKX cells: molecular insights and effector modulation of N-acetylglucosaminyltransferase I.Impact of IgG Fc-Oligosaccharides on Recombinant Monoclonal Antibody Structure, Stability, Safety, and Efficacy.Impact of Glycosylation on Effector Functions of Therapeutic IgGPharmacokinetics of monoclonal antibodies and Fc-fusion proteins.Impact of cell culture on recombinant monoclonal antibody product heterogeneity.Old dogs-new tricks: immunoregulatory properties of C3 and C5 cleavage fragments.Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose.Characterizing the effect of multiple Fc glycan attributes on the effector functions and FcγRIIIa receptor binding activity of an IgG1 antibody.Characterization of humanized antibodies secreted by Aspergillus niger.Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeysInitiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodiesEnhancement of toxin- and virus-neutralizing capacity of single-domain antibody fragments by N-glycosylation.
P2860
Q24291716-AE9C1261-C5BB-4C18-BDA1-B6AFA93EE225Q26799266-029E97BF-5A12-4689-9C18-9C3EC6538A10Q26859713-2E638DAB-E56A-4E5A-A531-31A6C611A3A8Q27314948-C6C6BE43-0B5F-48F8-9C2A-91B0F034F606Q27681704-6A56E0FD-CF61-4BC3-AAA3-6D0D341B566EQ28082880-7F587BD5-9419-46A6-A260-E10DCE03B297Q28218758-B08ED903-BBD4-4A84-BCE1-6E72B394F123Q31004131-30DFC1DE-B6FA-4938-8355-E1D7DFA1C4C3Q31962312-D1EED3B6-A981-41E8-908C-4DB72CA40E62Q33276349-B043EBAA-712A-4210-BAD4-2DC9C874E6EFQ33309958-66CD0178-42C6-4C5B-9F15-43A684ADD9C7Q33501332-FC372897-94BF-4227-B9C9-4DA0135567B7Q33565621-110B856B-0577-48D3-A203-F5BABD8617CAQ33829159-DEB96213-4386-43DD-BE52-CE6AE4D95B1CQ33986960-08D083BE-7B1D-4069-AD05-668DBF58115FQ34697409-665347D0-8F24-4788-BD73-F1F328FC8CA6Q35133183-2483AEAE-136F-4377-AA85-A571BD30D01FQ35689463-4BC49018-CC9E-48F8-9110-44C73A301936Q36211427-DA72F644-DC36-4A86-BE7C-50B35D6FBBE5Q36213158-68341F6E-9B90-425F-BC85-996D488B6D3AQ36216376-727104D2-5E6F-45A9-B13E-2EFCE7D8002CQ36402805-38564CE0-BFC9-489E-A999-69455B62911AQ36402812-5BE68E4C-F0A9-42A9-8617-CE49A1692905Q37734089-CFA1695E-FF63-4507-9C53-CD83066C41B9Q37776618-344B44A1-8D5D-44E1-8265-4F7A67030DA5Q38224264-23976145-800D-4500-AB46-4365A04EA841Q38308978-4C84A6E4-7CE0-47D3-BF25-23223AA8F059Q38318046-707A3059-ED26-49DC-98EE-BE252731BEB1Q38328602-0C69D54C-E27E-4E48-895F-DD26237A8F18Q38762019-95EA66AE-7411-425D-B84A-251ED6E95E1DQ38818688-C6767FF7-6090-4A45-852E-90CDEBF2C21CQ38831148-A461D12B-E18C-4450-A700-1C8CBDDF8A14Q38907094-8E8EA906-B8EC-4B3A-8B51-A6F89716D2BBQ38991048-11943B2B-927B-4268-A0D2-E552104F9CFAQ39590627-F6618816-DBB3-4411-895E-F019D5358887Q39782184-04E7668A-F554-4D59-BD63-E0CEC303987FQ40558843-EAC6D11F-CFE7-4CCF-8B47-4D8C97D67338Q41880655-EAC27F3D-CFE7-408E-8543-FDA0C45D322FQ42120792-C566BB98-2AEF-4439-9EB9-46F66677CB91Q42575198-1A38C06A-EF7F-4B3A-8839-4CF1BBD1F179
P2860
Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Effect of altered CH2-associat ...... mouse-human immunoglobulin G1.
@ast
Effect of altered CH2-associat ...... mouse-human immunoglobulin G1.
@en
type
label
Effect of altered CH2-associat ...... mouse-human immunoglobulin G1.
@ast
Effect of altered CH2-associat ...... mouse-human immunoglobulin G1.
@en
prefLabel
Effect of altered CH2-associat ...... mouse-human immunoglobulin G1.
@ast
Effect of altered CH2-associat ...... mouse-human immunoglobulin G1.
@en
P2860
P356
P1476
Effect of altered CH2-associat ...... mouse-human immunoglobulin G1.
@en
P2093
S L Morrison
P2860
P304
P356
10.1084/JEM.180.3.1087
P407
P577
1994-09-01T00:00:00Z